Scheduled for June 23 rd the CD19 Vaccine for cancer.A small company located in Texas will release it’s findings and results
from 110 clinical trials on a treatment centered on a patients immune
system where the T cell will recognize and phagotize the cancer cell.
The release of their findings should lead to licensing fees that should
cause the price of the stock to explode.
This is a discussion topic or guest posting submitted by a Stock Gumshoe reader. The content has not been edited or reviewed by Stock Gumshoe, and any opinions expressed are those of the author alone.
BPTH is unlikely. Their research on tumors has not even entered clinical trials. Also in the teasers many are referring to, there is no repeat no mention of the town being small. Only the company.
BLCM seems possible. Yet I am also looking at NK. Their business offices are on the west coast but their research facility could be elsewhere, as in Texas. Have not yet been able to run that down.
BLCM was up 70 cents in the after-market to close at $13.60. If shorts borrowed 4 million before today, some of the almost 3 million shares traded was short covering.
What was eye-opening is that one of the two presentations scheduled for Friday, June 23rd in Madrid is a “poster” presentation and neither relate to the CD19 vaccine nor does the presentation on June 24th. Tremblay mentions the purported results of the clinical trial will be announced at the hematology conference but I don’t see how or with which presentation or if it even if the conference is the proper forum for such an announcement.
Expect selling and losses tomorrow!
Thanks for the heads up guys – BLCM seems to match the indicators.
Initially i was looking at NK primarily because of their strong CEO which was one of the pitches throw out in the teaser.
388 was 338,000 which was grant income for 2016….this was not market cap as the person said in comparing it to 35M market cap for that bpth stock.
I watched the same sales pitch from Strategic Tech Investor all the way to the end. And as is typical of these subscription services, they want you to purchase yet another much more expensive subscription to get the real information you need to make the investment. I didn’t subscribe, because I feel it’s misleading and possibly a rip-off. I looked at BLCM on Fidelity’s website and the market cap for BLCM is $426.71M. The video stated $338k, with a potential of a $500M cash infusion through a licensing deal, which would catapult to 128,000% growth almost overnight. All teaser info with no promises in returns and looks to be speculative at best. Although the medical breakthrough sounds promising, and skeptical. Especially after reading a comment from a poster near the end of this thread stating that his uncle was informed of CD19 as a last resort, but that the doctors told him it only works ~ 20% of the time and there are side affects. The video makes no mention of the toxic side affects like conventional therapies (Chemo). Not sure which direction to go from here…
As a retired healthcare administrator, i have a LITTLE knowledge about medical patent law and how it pertains to medical and surgical clinical trials and investigations. I believe EVERYONE should THANK “La Storm’ for her research efforts. BLCM appears to be the correct choice IF we were NOT “thrown off” by the video sell…..EXCELLENT RESEARCH “La Storm” and, THANK YOU!! I will help you if you need help with setting up an investment account……
Bellicum http://www.bellicum.com does have a CD 19 Vaccine Program & will be presenting on June 23rd at the European Hematology Association, although presentation does not seem to be focused on CD 19 rather BPX-501.
Related to the CD 19 Vaccine Program is a working relationship w/ Ospedale Pediatrico Bambino Gesu (OPBG) of Rome.
So unlikely anything will happen on the 23rd as to CD19. Just another excuse to sell more $2000 subscriptions.
I’ve noticed some confusion about the nature of the $388,000 in this thread. The $388,000 is in relation to their 2016 fiscal year-end Sales – not market capitalization (two COMPLETELY different figures). The Sales for BLCM correspond exactly to $388,000 at year-end (2016) via COMPUSTAT data, which is all sourced from public SEC filings (2016 10-K). Who knows what kind of tricks the video is up to, but the $388,000 does align with BLCM’s 2016 Sales. I’m not sure where the market capitalization came into discussion. I’m about to dig into the research LA Storm did. Thank you for that!
UPDATE: I researched that event and two people from BLCM (Bellicum Pharmaceuticals Inc.) will be there and will be speaking (John Weinberg and Annemarie Moseley). I couldn’t track down much on John Weinberg (who may be an investor from Goldman Sachs, but I can’t confirm that), and Annemarie’s title is COO and EVP of Clinical Development. Also, Annemarie’s background and subject matter at the event does correspond to the aforementioned T Cells as it pertains to cancer and the immune system. So, for what it’s worth, that’s more promising news than discouraging news. As always, it’s hard to tell…
Thank you to all those who suggested Bellicum (BLCM). I’m going to give it a try. Can’t handle any more of the hour-long infomercial!!!! Thanks to all of you for your research and for blogging this suggestion!!!!!!
I am late to the party, but appreciate all the great research that has been done.
It looks like Bellicum is the consensus choice. A small investment, or wager is
my next action.
I am late to the party too, and thank you all for the research and comments. I think it is worth taking the risk. If wrong, may be a long term hold, but if right, nothing else can be better than this.
It looks like you’re right. Bellicum is it. I just emailed them asking if you can invest directly with them. Hope to hear tomorrow. I’m new to this stuff, so need to ask a lot of basic questions!
Did you get a reply on your question from them?
Dear Ehren, Can you please let me know what was the respond from them. Can invest directly with them? Thank you so much!
God beless you,
No reply as yet. Still waiting.
Did you get a hold of the company what did they say
Good luck to all. My take on it – Bellicum may be “below the radar” because they are presenting stem cell transplant data and not focussing on patient survival as the trial goal however there are many analysts commenting on them they are not invisible and the consensus is that they are undervalued – the average analyst price is $28 Vs price today of c$12. I dont think the 23rd June is 100% guaranteed as a huge trigger – the abstracts for any meeting are published well in advance and I think it is unwise to assume every analyst has missed this story – there are analysts at Goldmans, JP morgan etc sniffing 24h a day for huge gains and to assume all have missed it to me feels odd – we will soon find out. I think another important event is the 12th July ODAC review of the relevant Novartis drug – 50%+ of patients in the trial have cytokine issues – if the ODAC recommendation is that all CD19 drugs need a kill switch to gain approval then Bellicum and Ziopharma are well placed. My approach is going to be 1) put some funds into Bellicum and Ziopharm and see what the 23rd June and 12th July bring – if no major upsides sell some but keep some stake as this whole area has huge potential – it just might not be this Friday thats all which is what the teaser is trying to imply to create urgency to buy the report. Also of note – there has been no major inside buying of stock in recent times – and the co-founder of the company Kevin Slawin resigned yesterday – and there have been other high profile resignations this year – who knows the relevance – but knowing the facts is never a bad thing – good luck
I am going to be really upset if we have been fed a bunch of hype by these financial advisors who are making a lot of money charging us for their findings, if you want to call it that. We should file a class action lawsuit against them. Today, BLCM is DOWN and that shouldn’t be. I think CliveP has given us a good analysis. What is going on?
The financial advisors don’t care about you or your investments. All they want is your money foe their reports.
Hello CliveP, From your article I did learn more then I could find out of this issue the last couple of days. Thank you. I almost invested a program, /which will relive the Texas company name and the stock name to buy – many specialist program pop up now/ luckily I didn’t have the $2500,- fee for it. Looks like to me you have a better knowledge and understanding of this process. I am really appreciate if can give me further information on this subject. Unfortunately my husband had a bladder cancer, /was removed the bladder/ and now came back in the lymphoid system. So not just as an investment, / of course we last everything on the “treatment’s” /
but an hopefully as an available cure I am interested. Thank you for reading my comment. God bless you,
Dear Judith, just seen your note – very sorry to hear about your husbands condition and god bless that he will recover in full and quickly
Thank you so much!
Look what was announced by Moleculin Biotech … MBRX
Moleculin Announces Significant Discovery with Potential to Treat Pancreatic Cancer
Metabolic Inhibitor Shows Greater Ability to Kill Pancreatic Cancer Cell Lines
JoHi Sal, Where was announced?
BLCM doesn’t seem to have it’s own cd19 trials. However, in 2016 it announced expanded collaboration with Ospedale Pediatrico Bambino Gesù (OPBG), a leading European pediatric research center and hospital. The OPBG collaboration is focused on preclinical and clinical development of CD19 and other CAR T and TCR therapeutics engineered with Bellicum’s CaspaCIDe® molecular safety switch technology. Their agreement is:
The two organizations agreed to jointly develop CARs and other cell therapies discovered by OPBG and engineered with Bellicum’s CaspaCIDe safety switch, which is designed to reduce or eliminate cells that become toxic or are no longer needed. Under terms of this agreement, Bellicum agreed to provide financial support to the research collaboration in exchange for exclusive worldwide rights to commercialize certain cell therapies that are developed, while OPBG maintains rights for research purposes. OPBG will conduct research and clinical studies of CAR T and TCR therapeutics in pediatric patients, with initial CD19 CAR T and GD2 CAR T clinical trials in pediatric acute lymphoblastic leukemia and neuroblastoma patients, respectively, expected to start in 2017. In addition, OPBG agreed to manufacture European clinical trial supplies for the investigational programs, as well as Bellicum’s PRAME-targeted TCR, BPX-701, in its GMP facility.
I am thinking opbg may be presenting the big news that will make blcms safty switch blowup. BLCM also will get world wide rights on any therapy that OPBG has developed.
Thank you for the information!
Nov. 1, 2016– Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM) and Ospedale Pediatrico Bambino Gesù (OPBG), a leading European pediatric research center and hospital, today announced that they have entered into an expanded collaboration focused on preclinical and clinical development of CD19 and other CAR T and TCR therapeutics engineered with Bellicum’s CaspaCIDe® molecular safety switch technology.
The two organizations agreed to jointly develop CARs and other cell therapies discovered by OPBG and engineered with Bellicum’s CaspaCIDe safety switch, which is designed to reduce or eliminate cells that become toxic or are no longer needed. Under terms of this agreement, Bellicum agreed to provide financial support to the research collaboration in exchange for exclusive worldwide rights to commercialize certain cell therapies that are developed, while OPBG maintains rights for research purposes. OPBG will conduct research and clinical studies of CAR T and TCR therapeutics in pediatric patients, with initial CD19 CAR T and GD2 CAR T clinical trials in pediatric acute lymphoblastic leukemia and neuroblastoma patients, respectively, expected to start in 2017. In addition, OPBG agreed to manufacture European clinical trial supplies for the investigational programs, as well as Bellicum’s PRAME-targeted TCR, BPX-701, in its GMP facility.
Makes me think opbg will present the blockbuster announcement and will instantly make the blcm safety switch a high demand product. And also, if OPBG does make that big announcement, BLCM has world wide rights to it.
Sorry for the double post with basically the same info. I wrote 2 because my post wasn’t showing up. I repeated with another and it didn’t show up either. I emailed customer service at 3:45 and didn’t get response until 10:30 and found both had finally posted. Good luck to all and especially Judith. Hope you find a cure to help.
Thank you Dear, we really need it!
your research is fantastic, it is little late but I found JUNO also in 2nd phase of CD-19 and T cell clinical trial. They are not from Texas and their description does not match the teaser.
I just got on board. Will soon get the drift of the discusion.
So is is BLCM that is going to explode in the stock market?
BLCM’s abstracts have already been released. There likely will be no surprises on 6/23. I’d be concerned about people selling on the news or lack of news. Buy now at your own risk.
Mich, you are probably right, but I hope not. I have bought some options on blcm but I used stops just in case.
Stevex can I ask how you constructed and placed the option on this stock? I did bout the stock strait. Thank you!
Do you have a stock trading account? If so, you need to find out if you are approved for option trading. If all that is already set up I will be glad to help.
Dear Stevex, Yes I do have TradeKing/Ally account with level 3 for option trading. Before yesterday I bought 100 share of BLCM stock, which was up yesterday $112,- but today is down to $13,- profit. I don’t know how to put option on. I would like to sell /I think/ the stock, $1284,- is in stake. I am thank you for any help. My email is: jjg61752@aol.com Talk to you sun.
Hello Stevex, did you read my message? Thanks, waiting for your reply.
Ospedale Pediatrico Bambino Gesù is a children’s hospital in Rome, so I assume the play is still on Bellicum